drugset / Trial / NCT02933736
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
Phase 0
Active not recruiting
48 enrolled
Nader Sanai
Barrow Neurological Institute · collabIvy Brain Tumor Center · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 intervals before brain tumor resection.
Timeline
- Start
- 2016-10-17
- Primary completion
- 2023-03-01
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribociclib | Small molecule | 600 mg | Oral |
| Subject | Ribociclib | Small molecule | 900 mg | Oral |